100 related articles for article (PubMed ID: 38296279)
1. HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol.
Mathier E; Althaus A; Zwahlen D; Lustenberger J; Zamboglou C; De Bari B; Aebersold DM; Guckenberger M; Zilli T; Shelan M
BMJ Open; 2024 Jan; 14(1):e075846. PubMed ID: 38296279
[TBL] [Abstract][Full Text] [Related]
2. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
Kapoor R; Deek MP; McIntyre R; Raman N; Kummerlowe M; Chen I; Gaver M; Wang H; Denmeade S; Lotan T; Paller C; Markowski M; Carducci M; Eisenberger M; Beer TM; Song DY; DeWeese TL; Hearn JW; Greco S; DeVille C; Desai NB; Heath EI; Liauw S; Spratt DE; Hung AY; Antonarakis ES; Tran PT
BMC Cancer; 2019 Jun; 19(1):572. PubMed ID: 31196032
[TBL] [Abstract][Full Text] [Related]
3. Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy.
Lawal IO; Marcus C; Schuster DM; Goyal S; Adediran OA; Dhere VR; Joshi SS; Abiodun-Ojo OA; Master VA; Patel PR; Fielder B; Goodman M; Shelton JW; Kucuk O; Hershatter B; Halkar RK; Jani AB
Clin Nucl Med; 2023 Apr; 48(4):e153-e159. PubMed ID: 36754362
[TBL] [Abstract][Full Text] [Related]
4. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial.
Connor MJ; Shah TT; Smigielska K; Day E; Sukumar J; Fiorentino F; Sarwar N; Gonzalez M; Falconer A; Klimowska-Nassar N; Evans M; Naismith OF; Thippu Jayaprakash K; Price D; Gayadeen S; Basak D; Horan G; McGrath J; Sheehan D; Kumar M; Ibrahim A; Brock C; Pearson RA; Anyamene N; Heath C; Shergill I; Rai B; Hellawell G; McCracken S; Khoubehi B; Mangar S; Khoo V; Dudderidge T; Staffurth JN; Winkler M; Ahmed HU
BMJ Open; 2021 Feb; 11(2):e042953. PubMed ID: 33632752
[TBL] [Abstract][Full Text] [Related]
5. Randomized prospective phase III trial of
Calais J; Czernin J; Fendler WP; Elashoff D; Nickols NG
BMC Cancer; 2019 Jan; 19(1):18. PubMed ID: 30616601
[TBL] [Abstract][Full Text] [Related]
6. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
Ost P; Siva S; Brabrand S; Dirix P; Liefhooghe N; Otte FX; Gomez-Iturriaga A; Everaerts W; Shelan M; Conde-Moreno A; López Campos F; Papachristofilou A; Guckenberger M; Scorsetti M; Zapatero A; Villafranca Iturre AE; Eito C; Couñago F; Muto P; Van De Voorde L; Mach N; Bultijnck R; Fonteyne V; Moon D; Thon K; Mercier C; Achard V; Stellamans K; Goetghebeur E; Reynders D; Zilli T
Eur Urol Oncol; 2024 Jun; 7(3):462-468. PubMed ID: 37821242
[TBL] [Abstract][Full Text] [Related]
7. Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.
Dirix P; Strijbos M; den Mooter TV; Liefhooghe N; Bruwaene SV; Uvin P; Ghysel C; Ost D; Schatteman P; Bral S; Engels B; den Begin RV; Otte FX; Roumeguere T; Palumbo S; Neybuch Y; Fonteyne V; Ost P; Dirix L
Future Oncol; 2020 Jun; 16(16):1083-1189. PubMed ID: 32356465
[TBL] [Abstract][Full Text] [Related]
8. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
Calais J; Zhu S; Hirmas N; Eiber M; Hadaschik B; Stuschke M; Herrmann K; Czernin J; Kishan AU; Nickols NG; Elashoff D; Fendler WP
BMC Cancer; 2021 May; 21(1):512. PubMed ID: 33962579
[TBL] [Abstract][Full Text] [Related]
9. European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy.
Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Koerber SA; Debus J; Peeken JC; Vogel MME; Kroeze SGC; Guckenberger M; Krafcsik M; Hruby G; Emmett L; Schmidt-Hegemann NS; Trapp C; Spohn SKB; Henkenberens C; Mayer B; Shelan M; Aebersold DM; Thamm R; Wiegel T
Radiother Oncol; 2024 May; 194():110215. PubMed ID: 38458259
[TBL] [Abstract][Full Text] [Related]
10. Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial.
Müller AC; Zips D; Heinrich V; Lamprecht U; Voigt O; Burock S; Budach V; Wust P; Ghadjar P
Radiat Oncol; 2015 Jul; 10():138. PubMed ID: 26152590
[TBL] [Abstract][Full Text] [Related]
11. SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer.
Stranne J; Brasso K; Brennhovd B; Johansson E; Jäderling F; Kouri M; Lilleby W; Meidahl Petersen P; Mirtti T; Pettersson A; Rannikko A; Thellenberg C; Akre O
Scand J Urol; 2018; 52(5-6):313-320. PubMed ID: 30585526
[TBL] [Abstract][Full Text] [Related]
12. Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial.
Reddy D; Shah TT; Dudderidge T; McCracken S; Arya M; Dobbs C; Emberton M; Fiorentino F; Day E; Prevost AT; Staffurth J; Sydes M; Winkler M; Ahmed HU
Contemp Clin Trials; 2020 Jun; 93():105999. PubMed ID: 32302790
[TBL] [Abstract][Full Text] [Related]
13. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
Morgan TM; Boorjian SA; Buyyounouski MK; Chapin BF; Chen DYT; Cheng HH; Chou R; Jacene HA; Kamran SC; Kim SK; Kirkby E; Luckenbaugh AN; Nathanson BJ; Nyame YA; Posadas EM; Tran PT; Chen RC
J Urol; 2024 Apr; 211(4):509-517. PubMed ID: 38421253
[TBL] [Abstract][Full Text] [Related]
14. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
Morgan TM; Boorjian SA; Buyyounouski MK; Chapin BF; Chen DYT; Cheng HH; Chou R; Jacene HA; Kamran SC; Kim SK; Kirkby E; Luckenbaugh AN; Nathanson BJ; Nyame YA; Posadas EM; Tran PT; Chen RC
J Urol; 2024 Apr; 211(4):518-525. PubMed ID: 38421243
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy.
Rodler S; Danninger D; Eismann L; Kazmierczak PM; Jokisch F; Li M; Becker A; Kretschmer A; Stief C; Westhofen T
World J Urol; 2024 Apr; 42(1):242. PubMed ID: 38635030
[TBL] [Abstract][Full Text] [Related]
16. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
Morgan TM; Boorjian SA; Buyyounouski MK; Chapin BF; Chen DYT; Cheng HH; Chou R; Jacene HA; Kamran SC; Kim SK; Kirkby E; Luckenbaugh AN; Nathanson BJ; Nyame YA; Posadas EM; Tran PT; Chen RC
J Urol; 2024 Apr; 211(4):526-532. PubMed ID: 38421252
[TBL] [Abstract][Full Text] [Related]
17. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
König L; Dreyling M; Dürig J; Engelhard M; Hohloch K; Viardot A; Witzens-Harig M; Kieser M; Klapper W; Pott C; Herfarth K
Trials; 2019 Aug; 20(1):544. PubMed ID: 31470902
[TBL] [Abstract][Full Text] [Related]
18. A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial.
Hudson EM; Noutch S; Brown S; Adapala R; Bach SP; Burnett C; Burrage A; Gilbert A; Hawkins M; Howard D; Jefford M; Kochhar R; Saunders M; Seligmann J; Smith A; Teo M; Webb EJ; Webster A; West N; Sebag-Montefiore D; Gollins S; Appelt AL
BMJ Open; 2022 Apr; 12(4):e049119. PubMed ID: 35487526
[TBL] [Abstract][Full Text] [Related]
19. Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy.
Robin S; Jolicoeur M; Palumbo S; Zilli T; Crehange G; De Hertogh O; Derashodian T; Sargos P; Salembier C; Supiot S; Udrescu C; Chapet O
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1243-1253. PubMed ID: 33186618
[TBL] [Abstract][Full Text] [Related]
20. Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE".
Marvaso G; Corrao G; Repetti I; Lorubbio C; Bellerba F; Zaffaroni M; Vincini MG; Zerini D; Alessi S; Luzzago S; Mistretta FA; Fodor C; Cambria R; Cattani F; Ceci F; Musi G; De Cobelli O; Zilli T; Gandini S; Orecchia R; Petralia G; Jereczek-Fossa BA
World J Urol; 2024 Mar; 42(1):169. PubMed ID: 38492078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
